Company News

newsicon-company

This section of pediculosis.com is devoted to news about corporate developments and company announcements.

03.04.12 | New head lice product? Phytalexin and Eden Agreement

An agreement dated 19 March 2012 has been made between Eden Research plc, an agrochemical and encapsulation technology company, and Phytalexin Ltd. This grants Phytalexin exclusive rights to Eden's formulations and encapsulation technologies for use in a head-lice product.

14.03.12 | Foamix granted US Patent for PerFoam lice treatment

Foamix Ltd., the Israeli speciality pharma company, announced on 12 March 2012 that they had been granted a US patent for their PerFoam head lice treatment.

28.02.12 | Omega Pharma MBO gains over 99% of shares

Omega Pharma have disclosed that the MBO by Couckinvest NV has succeeded in gaining over 99% of shares during the squeeze-out process.

08.02.12 | Sanofi purchases Topaz for lice drug

Topaz Pharmaceuticals has been acquired by Sanofi-Pasteur, the vaccines unit of French pharmaceutical company Sanofi-Aventis, according to a report by the Philadelphia Business Journal published 3 February 2012.

01.02.12 | Update on Omega Pharma takeover

Omega Pharma have confirmed that the takeover process initiated by Couckinvest NV now holds over 97% of shares.

31.01.12 | Natroba Update

The American Academy of Pediatrics was given an update on Natroba (spinosad) at its 2011 national conference and exhibition...

22.12.11 | Rosemary Repel salon deal

Fairy Tales Hair Care has sealed a US-wide distribution deal with SalonCentric for its Rosemary Repel® Lice Prevention System...

07.06.11 | FDA accepts Topaz NDA

The US Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Topaz Pharmaceuticals...

27.04.11 | ASA bans online lice ad

The UK Advertising Standards Authority (ASA) has banned an internet promotion for a head lice repelling product...

Join us on Twitter

Site Map   |    Privacy Policy   |   Terms & Conditions

© 2012-2013 pediculosis.com — all rights reserved